TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00707382

Intervention type: GENETIC
Group type: OTHER
Intervention: (1) Genotyping for CYP4502D6 and 2C19 polymorphisms
Description: In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described.

Intervention type: OTHER
Group type: OTHER
Intervention: (2) Intense clinical monitoring
Description: In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: (3) Control
Description: In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
Study: NCT02554136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918
Study: NCT02550990

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential combination of aerobic exercise and cognitive training
Study: NCT03478332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yangxinshi pill
Description: 0.6g/tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conventional coronary heart disease medicine
Description: the conventional treatment includes medicines treating coronary heart disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional coronary heart disease medicine
Description: the conventional treatment includes medicines treating coronary heart disease

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Yangxinshi simulant
Study: NCT03323541

Intervention type: DRUG
Intervention: Filgrastim Prefilled Syringe [Zarzio®]
Description: Daily subcutaneous injection of Zarxio post ASCT, from day 5 until bone marrow recovery (neutrophils \>1 giga/l)
Study: NCT02143323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin tablet
Study: NCT03590093

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery
Description: After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMD application
Description: Application of Pref-Gel for 2 minutes and then the application on Enamel Matrix Derivatives on the surgically exposed root surface
Study: NCT02820038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Guides
Description: The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication Guides
Description: The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
Study: NCT01687998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered Orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally
Study: NCT01898806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone 2.5 mg/ml
Description: Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone 5 mg/ml
Description: Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone 10 mg/ml
Description: Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intralesional Saline
Description: Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
Study: NCT02820038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Program
Description: The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Program
Description: The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug Facts Boxes
Description: The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug Facts Boxes
Description: The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
Study: NCT03209011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Study: NCT03658798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Study participants will receive 40 sessions of intervention, 3 to 5 times a week over 2 to 3 months. Each session will be one hour in duration and participant will receive functional electrical stimulation therapy with their customized shirt. During therapy participants will be expected to carry out functional movements with assistance from the FES Garment.Participants will be expected to don, activate, and doff the garment as independently as possible. The exercises conducted will be defined by the investigator based on the functional status of the participant and eventual progress.
Study: NCT04295707

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthokeratology
Description: Nightly wear of orthokeratology lenses to correct vision in the daytime

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthokeratology
Description: Nightly wear of orthokeratology lenses to correct vision in the daytime

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthokeratology
Description: Nightly wear of orthokeratology lenses to correct vision in the daytime

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Menicon Progent A+B
Description: Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Menicon Progent A+B
Description: Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
Study: NCT01766544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice Group (SPG)
Description: The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TISG
Description: interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
Study: NCT01000818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0518 (Raltegravir)
Description: 400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0518 (Raltegravir)
Description: 400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0518 (Raltegravir)
Description: 400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famotidine
Description: Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: 20 mg oral tablet of omeprazole, once daily for 5 days
Study: NCT02979561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
Study: NCT03785444

Intervention type: OTHER
Intervention: WHODAS 2.0
Description: WHO Disability Score

Intervention type: OTHER
Intervention: WHODAS 2.0
Description: WHO Disability Score

Intervention type: OTHER
Intervention: EQ5D
Description: Health related quality of life measured with European Quality of Life 5 Dimensions 5 Level

Intervention type: OTHER
Intervention: EQ5D
Description: Health related quality of life measured with European Quality of Life 5 Dimensions 5 Level

Intervention type: OTHER
Intervention: IADL
Description: The Lawton Instrumental Activities of Daily Living

Intervention type: OTHER
Intervention: IADL
Description: The Lawton Instrumental Activities of Daily Living

Intervention type: OTHER
Intervention: Barthel-Score
Description: Barthel Score of the patient

Intervention type: OTHER
Intervention: Barthel-Score
Description: Barthel Score of the patient

Intervention type: OTHER
Intervention: SF-36
Description: Short Form Health 36

Intervention type: OTHER
Intervention: SF-36
Description: Short Form Health 36

Intervention type: OTHER
Intervention: MoCA Blind
Description: Montreal Cognitive Assessment

Intervention type: OTHER
Intervention: MoCA Blind
Description: Montreal Cognitive Assessment
Study: NCT01390038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simpliciti™ Shoulder System
Description: Total shoulder arthroplasty system
Study: NCT03898388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate treatment
Description: Correlate patient outcomes 6 months after receiving the Regenexx SD treatment with measurements of synovial fluid collected before treatment
Study: NCT01369446

Intervention type: DEVICE
Intervention: Eeva System Study
Description: The Eeva System will image embryos through cleavage and/or blastocyst stage.
Study: NCT00383708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: 120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
Study: NCT04348786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycylcine 100 mg bid ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
Study: NCT01843634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODSH
Study: NCT02396693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) \< 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) \< 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bubble NCPAP
Description: Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ventilator NCPAP
Description: Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
Study: NCT03577951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high position space group
Description: The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low position space group
Description: The left and right Trocar meet under the sternum angle and begin to establish the operating space.
Study: NCT01841489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1600 mg GS-9973 (Formulation 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1600 mg GS-9973 (Formulation 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: 1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: 1600 mg GS-9973 (Formulation 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: 1600 mg GS-9973 (Formulation 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: 1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: 1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment G
Description: 1600 mg GS-9973 (Reference formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment G
Description: 1600 mg GS-9973 (Reference formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment H
Description: 1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment H
Description: 1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment I
Description: An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment I
Description: An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment J
Description: An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment J
Description: An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
Study: NCT00368472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Perampanel 2 mg to 12 mg, once daily during the OLE study
Study: NCT01570452

Intervention type: PROCEDURE
Intervention: colonic or colorectal resection
Description: standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection

Intervention type: PROCEDURE
Intervention: colonic or colorectal resection
Description: standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection

Intervention type: PROCEDURE
Intervention: colonic or colorectal resection
Description: standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection

Intervention type: PROCEDURE
Intervention: colonic or colorectal resection
Description: standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
Study: NCT03615989

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance and Plyometric Exercise
Description: A single resistance and plyometric exercise bout per trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance and Plyometric Exercise
Description: A single resistance and plyometric exercise bout per trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate (Maltodextrin powder mixed with water)
Description: 50 grams immediately after exercise bout. 50 grams 1 hour after exercise bout.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skim Milk
Description: 500 ml immediately after exercise bout. 500 ml 1 hour after exercise bout.
Study: NCT02574481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELUVIA (Stent Implantation)
Description: Drug-eluting self-expanding stent implantation during the index procedure.
Study: NCT02554136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816
Study: NCT02574481

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zilver PTX (Stent Implantation)
Description: Drug-eluting self-expanding stent implantation during the index procedure.
Study: NCT00796003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-30979754 15 mg/m2
Description: JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.